Celastrol suppresses human pancreatic cancer via m⁶A-YTHDF3-mediated downregulation of Claspin and Bcl-2.

ABSTRACT:

Background

Celastrol has been revealed to exhibit anticancer pharmacological activity, however, the molecular mechanisms of celastrol involved in pancreatic cancer remain to be further elucidated. The present study was to illustrate whether celastrol suppresses pancreatic cancer through modulating RNA m⁶A modification.

Methods

Effect of celastrol treatment on the malignant phenotypes of pancreatic cancer cells was evaluated by CCK-8 assay, EdU assay, colony formation assay, flow cytometry analysis and subcutaneous xenograft experiments. RNA sequencing (RNA-seq) analysis was carried out to analyze the genes differentially expressed in celastrol-treated pancreatic cancer cells. RT-qPCR, Western blotting and immunohistochemistry were employed to evaluate the expressi

SUBMITTER: Zhou Y 

PROVIDER: S-EPMC10728403 | biostudies-literature | 2023 Dec

REPOSITORIES: biostudies-literature